Skip Navigation


Carcinogenesis Advance Access originally published online on February 28, 2008
Carcinogenesis 2008 29(5):895-904; doi:10.1093/carcin/bgn017
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
29/5/895    most recent
bgn017v2
bgn017v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Licchesi, J. D.F.
Right arrow Articles by Herman, J. G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Licchesi, J. D.F.
Right arrow Articles by Herman, J. G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung

Julien D.F. Licchesi1, William H. Westra2, Craig M. Hooker1, Emi O. Machida1, Stephen B. Baylin1 and James G. Herman1,*

1 Cancer Biology Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2 Department of Pathology, the Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA

* To whom correspondence should be addressed. Tel: +1 410 955 8506; Fax: +1 410 614 9884; Email: hermanji{at}jhmi.edu

Background: Atypical adenomatous hyperplasia (AAH) is now recognized as a precursor lesion from which lung adenocarcinomas arise and thus represents an ideal target for studying the early genetic and epigenetic alterations associated with lung tumorigenesis such as alterations of the Wnt pathway. Methods: We assessed the level of Wnt signaling activity in lung cancer cell lines by determining the level of active β-catenin and determined the level of expression of Wnt antagonists APC, DKK1, DKK3, LKB1, SFRP1, 2, 4, 5, WIF1 and RUNX3 using reverse transcription–polymerase chain reaction. Using multiplex nested methylation-specific polymerase chain reaction, we analyzed promoter region methylation of these genes in resected lung tissue in the histopathologic sequence of glandular neoplasia (normal lung parenchyma, low-grade and high-grade AAH, adenocarcinoma). Results: The majority of non-small cell lung cancer cell lines (11 of 16, 69%) have evidence of active Wnt signaling and silencing of Wnt antagonists correlated with promoter hypermethylation. Promoter region methylation of Wnt antagonists was common in primary lung adenocarcinoma and there was a significant increase in the frequency of methylation for Wnt antagonist genes and the number of genes methylated with each stage of tumorigenesis (test for rend P ≤ 0.01). Additionally, odds ratios for promoter hypermethylation of individual or multiple Wnt antagonist genes and adenocarcinomas were statistically significantly elevated and ranged between 3.64 and 48.17. Conclusion: These results show that gene silencing of Wnt antagonists by promoter hypermethylation occurs during the earliest stages of glandular neoplasia of the lung and accumulates with progression toward malignancy.

Abbreviations: AAH, atypical adenomatous hyperplasia; HG-AAH, high-grade atypical adenomatous hyperplasia; LG-AAH, low-grade atypical adenomatous hyperplasia; MSP, methylation-specific polymerase chain reaction; NSCLC, non-small cell lung cancer; RT–PCR, reverse transcription–polymerase chain reaction; TCF, T cell factor

Received October 9, 2007; revised December 18, 2007; accepted January 4, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.